This program is 1 of 3 virtual symposia offered in partnership with HOPA that include patient counseling videos to demonstrate “best practice” pharmacist communication with patients.
Program Description
A large proportion of patients with multiple myeloma (MM) fail to respond to or have a short duration of response to treatment, making progression to relapsed/refractory disease an anticipated part of the disease course. B-cell maturation antigen (BCMA) has emerged as a potential therapeutic target in MM, with several modalities currently FDA approved and others under investigation. Though BCMA-directed agents have advanced the treatment of relapsed/refractory MM, they are associated with toxicities that can be severe and that can result in dose modifications, treatment delays, and discontinuation. Oncology pharmacists should be familiar with the various mechanisms and modalities currently available to best assist in selection of BCMA-targeted therapy based on patient- and disease-specific factors. Strategies for monitoring and management of toxicities associated with BCMA-targeted agents will be reviewed. This activity also has patient counseling videos featuring interactions between an oncology pharmacist and a patient with MM that will offer participants insights into important educational points, including adverse effect management, of BCMA-directed agents.
Target audience: Health-system and oncology pharmacists
Type of activity: Application
Release date: December 14, 2022
Expiration date: February 29, 2024
Time to complete activity: 1.25 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Compare pharmacologic characteristics of B-cell maturation antigen (BCMA)-directed therapies in relapsed/refractory multiple myeloma (RRMM)
- Explore clinical data for approved and emerging BCMA-targeted therapies for the management of RRMM
- Personalize BCMA-directed treatment for patients with RRMM based on patient- and disease-specific characteristics
- Identify pharmacist-driven strategies to optimize treatment outcomes and overall care for patients receiving BCMA-directed therapy for RRMM
Kathryn Maples, PharmD, BCOP
Clinical Pharmacy Specialist, Multiple Myeloma
Winship Cancer Institute
Atlanta, Georgia
Joseph Kalis, PharmD, BCOP
Ambulatory Oncology Pharmacist
UCHealth Hematology/Oncology
Colorado Springs, Colorado
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-22-600-H01-P. The activity is available for CE credit through February 29, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Joseph Kalis, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Speakers Bureau: GlaxoSmithKline, Oncopeptides
Kathryn Maples, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: GlaxoSmithKline, Sanofi, Karyopharm, Pfizer, Janssen
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA; Amy L. Morris, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms